Home / BMRN : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does BMRN make money? Does BMRN have pricing power? What's the Earnings Whisper? Will BMRN profit more as the business scales? What is BMRN's management track record? Is BMRN's current price justified?

BioMarin Pharmaceutical Inc.

$65.68 +$6.23 (+10.48%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$65.51

Day Range

$65.28$66

Year Range

$49.26$70.98

Market Cap

12.69B

AVG Volume

2.11M

Trailing/Forward PE

172.84/9.86

PEG ratio

5.33

Dividend Yield

Next Earnings Date

2026-10-26

Primary Exchange

NASDAQ

Revenue (USD)

BMRN Revenue (USD) by year
Period	Revenue (USD)
2025	3.22B
2024	2.85B
2023	2.42B
2022	2.1B
2021	1.85B
2020	1.86B
2019	1.7B
2018	1.49B
2017	1.31B
2016	1.12B

Net Income (USD)

BMRN Net Income (USD) by year
Period	Net Income (USD)
2025	348.9M
2024	426.86M
2023	167.65M
2022	141.56M
2021	-64.08M
2020	859.1M
2019	-23.85M
2018	-77.21M
2017	-117.04M
2016	-618.2M

Operating Income (USD)

BMRN Operating Income (USD) by year
Period	Operating Income (USD)
2025	533.48M
2024	484.21M
2023	172.71M
2022	149.56M
2021	-82.34M
2020	-36.77M
2019	-100.46M
2018	-123.52M
2017	-14.7M
2016	-803.43M

EBITDA (USD)

BMRN EBITDA (USD) by year
Period	EBITDA (USD)
2025	572.94M
2024	650.53M
2023	309.69M
2022	266.92M
2021	47.43M
2020	91.64M
2019	32.93M
2018	-6.98M
2017	90.97M
2016	-698.01M

Cash Flows (USD)

BMRN Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	719.65M
2024	475.42M
2023	51.65M
2022	44.36M
2021	188.96M
2020	-36.27M
2019	-105.09M
2018	-124.41M
2017	-207.98M
2016	-376.22M

EPS (USD)

BMRN EPS (USD) by year
Period	EPS (USD)
2025	1.8
2024	2.2
2023	0.87
2022	0.73
2021	-0.36
2020	4.41
2019	-0.15
2018	-0.44
2017	-0.67
2016	-3.93

Expenses (USD)

BMRN Expenses (USD) by year
Period	Expenses (USD)
2025	2.54B
2024	1.85B
2023	1.72B
2022	1.64B
2021	1.5B
2020	1.49B
2019	1.55B
2018	1.45B
2017	1.36B
2016	1.29B

Cash & Debt (USD)

BMRN Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	1.56B
2024	1.14B
2023	1.07B
2022	1.29B
2021	1.01B
2020	1.07B
2019	753.81M
2018	1.08B
2017	1.4B
2016	789.68M

Debt ratios

BMRN Debt ratios by year
Period	Debt ratios
2025	-0.51
2024	-0.42
2023	0.03
2022	-0.45
2021	0.46
2020	0.1
2019	-0.18
2018	0.37

Margins

BMRN Margins by year
Period	Margins
2025	77.13%
2024	79.67%
2023	78.11%
2022	76.92%
2021	74.52%
2020	71.82%
2019	78.91%
2018	78.86%
2017	81.59%
2016	81.23%

Return on Capital

BMRN Return on Capital by year
Period	Return on Capital
2025	5.73%
2024	7.54%
2023	3.39%
2022	3.08%
2021	-1.5%
2020	20.92%
2019	-0.76%
2018	-2.6%
2017	-4.17%
2016	-22.35%

Shares Outstanding

BMRN Shares Outstanding by year
Period	Shares Outstanding
2025	191.79M
2024	190.69M
2023	188.48M
2022	186.03M
2021	181.6M
2020	181.44M
2019	179.53M
2018	177.94M
2017	175.49M
2016	172.01M

Book Value Per Share (USD)

BMRN Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	31.74
2024	29.67
2023	26.27
2022	24.74
2021	23.49
2020	22.63
2019	17.39
2018	16.68
2017	16.01
2016	16.08

Total Assets (USD)

BMRN Total Assets (USD) by year
Period	Total Assets (USD)
2025	7.59B
2024	6.99B
2023	6.84B
2022	6.38B
2021	6B
2020	5.85B
2019	4.69B
2018	4.43B
2017	4.63B
2016	4.02B

Employee Count

BMRN Employee Count by year
Period	Employee Count
2025	3.22K
2024	3.04K
2023	3.4K
2022	3.08K
2021	3.04K
2020	3.06K
2019	3K
2018	2.85K
2017	2.58K
2016	2.29K

PE Ratio

BMRN PE Ratio by year
Period	PE Ratio
Sep 26	173.68
Sep 26	175.92
Aug 26	171.01
Aug 26	176.37
Aug 26	178.12
Aug 26	168.73
Jul 26	42.99
Jul 26	42.5
Jul 26	42.68
Jul 26	42.35
Jul 26	42.25
Jun 26	42.26
Jun 26	39.17
Jun 26	40.08
Jun 26	40.66
May 26	41.04
May 26	38.74
May 26	37.11
May 26	38.72
May 26	29.72
Apr 26	29.23
Apr 26	30.04
Apr 26	29.97
Apr 26	30.51
Mar 26	29.76
Mar 26	29.75
Mar 26	32.16
Mar 26	33.6
Feb 26	33.93
Feb 26	23.65
Feb 26	22.09
Feb 26	21.45
Jan 26	20.86
Jan 26	20.74
Jan 26	20.14
Jan 26	21.75
Jan 26	21.94
Dec 25	22.12
Dec 25	22.56
Dec 25	19.67
Dec 25	19.7
Nov 25	20.64
Nov 25	20.18
Nov 25	20.2
Nov 25	18.99
Oct 25	19.77
Oct 25	15.87
Oct 25	15.52
Oct 25	15.24
Oct 25	16.15
Sep 25	15.69
Sep 25	15.83
Sep 25	15.76
Sep 25	16.83
Aug 25	16.97
Aug 25	17.06
Aug 25	16.76
Aug 25	16.7
Aug 25	21.19
Jul 25	21.51
Jul 25	20.88
Jul 25	21.18
Jul 25	20.96
Jun 25	20.11
Jun 25	20.05
Jun 25	20.49
Jun 25	20.65
May 25	21.17
May 25	20.98
May 25	21.61
May 25	21.46
May 25	22.61
Apr 25	28.28
Apr 25	26.43
Apr 25	25.38
Apr 25	26.92
Mar 25	31.91
Mar 25	31.82
Mar 25	31.02
Mar 25	32.27
Feb 25	31.79
Feb 25	40.33
Feb 25	38.32
Feb 25	37.77
Jan 25	37.44
Jan 25	36.47
Jan 25	36.36
Jan 25	39.81
Jan 25	39.49
Dec 24	39.52
Dec 24	38.8
Dec 24	39
Dec 24	39.43
Nov 24	39.01
Nov 24	37.97
Nov 24	37.47
Nov 24	39.63
Nov 24	39.35
Oct 24	51.66
Oct 24	51.95

Free Cash Flow Yield

BMRN Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	5.78%
Sep 26	5.71%
Aug 26	5.87%
Aug 26	5.69%
Aug 26	5.64%
Aug 26	5.95%
Jul 26	6.59%
Jul 26	6.67%
Jul 26	6.64%
Jul 26	6.69%
Jul 26	6.71%
Jun 26	6.71%
Jun 26	7.24%
Jun 26	7.07%
Jun 26	6.97%
May 26	6.91%
May 26	7.32%
May 26	7.64%
May 26	7.32%
May 26	6.94%
Apr 26	7.06%
Apr 26	6.87%
Apr 26	6.88%
Apr 26	6.76%
Mar 26	6.93%
Mar 26	6.93%
Mar 26	6.41%
Mar 26	6.14%
Feb 26	6.08%
Feb 26	6.71%
Feb 26	7.19%
Feb 26	7.4%
Jan 26	7.61%
Jan 26	7.65%
Jan 26	7.88%
Jan 26	7.3%
Jan 26	7.24%
Dec 25	7.18%
Dec 25	7.03%
Dec 25	8.07%
Dec 25	8.06%
Nov 25	7.69%
Nov 25	7.87%
Nov 25	7.86%
Nov 25	8.36%
Oct 25	8.03%
Oct 25	6.63%
Oct 25	6.78%
Oct 25	6.9%
Oct 25	6.52%
Sep 25	6.71%
Sep 25	6.64%
Sep 25	6.68%
Sep 25	6.25%
Aug 25	6.2%
Aug 25	6.17%
Aug 25	6.28%
Aug 25	6.3%
Aug 25	5.59%
Jul 25	5.5%
Jul 25	5.67%
Jul 25	5.59%
Jul 25	5.65%
Jun 25	5.89%
Jun 25	5.9%
Jun 25	5.78%
Jun 25	5.73%
May 25	5.59%
May 25	5.64%
May 25	5.48%
May 25	5.52%
May 25	5.24%
Apr 25	3.94%
Apr 25	4.21%
Apr 25	4.39%
Apr 25	4.14%
Mar 25	3.49%
Mar 25	3.5%
Mar 25	3.59%
Mar 25	3.45%
Feb 25	3.5%
Feb 25	2.32%
Feb 25	2.44%
Feb 25	2.47%
Jan 25	2.49%
Jan 25	2.56%
Jan 25	2.57%
Jan 25	2.34%
Jan 25	2.36%
Dec 24	2.36%
Dec 24	2.41%
Dec 24	2.39%
Dec 24	2.37%
Nov 24	2.39%
Nov 24	2.46%
Nov 24	2.49%
Nov 24	2.36%
Nov 24	2.37%
Oct 24	1.61%
Oct 24	1.6%

Price to Sales

BMRN Price to Sales by year
Period	Price to Sales
Sep 26	3.72
Sep 26	3.77
Aug 26	3.66
Aug 26	3.78
Aug 26	3.82
Aug 26	3.61
Jul 26	3.56
Jul 26	3.52
Jul 26	3.54
Jul 26	3.51
Jul 26	3.5
Jun 26	3.5
Jun 26	3.25
Jun 26	3.32
Jun 26	3.37
May 26	3.4
May 26	3.21
May 26	3.08
May 26	3.21
May 26	3.22
Apr 26	3.17
Apr 26	3.25
Apr 26	3.25
Apr 26	3.3
Mar 26	3.22
Mar 26	3.22
Mar 26	3.48
Mar 26	3.64
Feb 26	3.68
Feb 26	3.98
Feb 26	3.72
Feb 26	3.61
Jan 26	3.51
Jan 26	3.49
Jan 26	3.39
Jan 26	3.66
Jan 26	3.69
Dec 25	3.72
Dec 25	3.8
Dec 25	3.31
Dec 25	3.31
Nov 25	3.47
Nov 25	3.39
Nov 25	3.4
Nov 25	3.19
Oct 25	3.32
Oct 25	3.4
Oct 25	3.33
Oct 25	3.27
Oct 25	3.46
Sep 25	3.37
Sep 25	3.4
Sep 25	3.38
Sep 25	3.61
Aug 25	3.64
Aug 25	3.66
Aug 25	3.6
Aug 25	3.58
Aug 25	3.76
Jul 25	3.82
Jul 25	3.71
Jul 25	3.76
Jul 25	3.72
Jun 25	3.57
Jun 25	3.56
Jun 25	3.64
Jun 25	3.67
May 25	3.76
May 25	3.73
May 25	3.84
May 25	3.81
May 25	4.02
Apr 25	4.23
Apr 25	3.95
Apr 25	3.8
Apr 25	4.03
Mar 25	4.77
Mar 25	4.76
Mar 25	4.64
Mar 25	4.83
Feb 25	4.75
Feb 25	4.72
Feb 25	4.49
Feb 25	4.42
Jan 25	4.38
Jan 25	4.27
Jan 25	4.26
Jan 25	4.66
Jan 25	4.62
Dec 24	4.63
Dec 24	4.54
Dec 24	4.57
Dec 24	4.62
Nov 24	4.57
Nov 24	4.45
Nov 24	4.39
Nov 24	4.64
Nov 24	4.61
Oct 24	5.12
Oct 24	5.15

EV/EBITDA

BMRN EV/EBITDA by year
Period	EV/EBITDA
Sep 26	41.49
Sep 26	41.91
Aug 26	40.98
Aug 26	42
Aug 26	42.33
Aug 26	40.55
Jul 26	22.32
Jul 26	22.05
Jul 26	22.15
Jul 26	21.96
Jul 26	21.91
Jun 26	21.92
Jun 26	20.2
Jun 26	20.7
Jun 26	21.03
May 26	21.23
May 26	19.96
May 26	19.05
May 26	19.95
May 26	16.49
Apr 26	16.2
Apr 26	16.69
Apr 26	16.65
Apr 26	16.98
Mar 26	16.52
Mar 26	16.52
Mar 26	17.98
Mar 26	18.86
Feb 26	19.06
Feb 26	14.8
Feb 26	13.75
Feb 26	13.32
Jan 26	12.93
Jan 26	12.84
Jan 26	12.44
Jan 26	13.53
Jan 26	13.65
Dec 25	13.77
Dec 25	14.07
Dec 25	12.12
Dec 25	12.15
Nov 25	12.77
Nov 25	12.47
Nov 25	12.48
Nov 25	11.66
Oct 25	12.19
Oct 25	10.28
Oct 25	10.04
Oct 25	9.84
Oct 25	10.47
Sep 25	10.15
Sep 25	10.25
Sep 25	10.2
Sep 25	10.95
Aug 25	11.06
Aug 25	11.12
Aug 25	10.91
Aug 25	10.86
Aug 25	13.42
Jul 25	13.64
Jul 25	13.22
Jul 25	13.41
Jul 25	13.27
Jun 25	12.69
Jun 25	12.65
Jun 25	12.95
Jun 25	13.06
May 25	13.41
May 25	13.28
May 25	13.7
May 25	13.6
May 25	14.38
Apr 25	17.73
Apr 25	16.52
Apr 25	15.83
Apr 25	16.84
Mar 25	20.12
Mar 25	20.06
Mar 25	19.53
Mar 25	20.35
Feb 25	20.04
Feb 25	25
Feb 25	23.72
Feb 25	23.38
Jan 25	23.16
Jan 25	22.55
Jan 25	22.48
Jan 25	24.67
Jan 25	24.47
Dec 24	24.49
Dec 24	24.03
Dec 24	24.16
Dec 24	24.43
Nov 24	24.17
Nov 24	23.5
Nov 24	23.19
Nov 24	24.56
Nov 24	24.38
Oct 24	31.16
Oct 24	31.33

Price/Operating Cashflow

BMRN Price/Operating Cashflow by year
Period	Price/Operating Cashflow
Sep 26	14.79
Sep 26	14.98
Aug 26	14.56
Aug 26	15.02
Aug 26	15.16
Aug 26	14.37
Jul 26	13.22
Jul 26	13.06
Jul 26	13.12
Jul 26	13.02
Jul 26	12.99
Jun 26	12.99
Jun 26	12.04
Jun 26	12.32
Jun 26	12.5
May 26	12.61
May 26	11.91
May 26	11.41
May 26	11.9
May 26	12.52
Apr 26	12.32
Apr 26	12.66
Apr 26	12.63
Apr 26	12.86
Mar 26	12.54
Mar 26	12.54
Mar 26	13.55
Mar 26	14.16
Feb 26	14.3
Feb 26	13.46
Feb 26	12.58
Feb 26	12.21
Jan 26	11.88
Jan 26	11.81
Jan 26	11.47
Jan 26	12.39
Jan 26	12.49
Dec 25	12.6
Dec 25	12.85
Dec 25	11.2
Dec 25	11.22
Nov 25	11.75
Nov 25	11.49
Nov 25	11.5
Nov 25	10.81
Oct 25	11.26
Oct 25	13.6
Oct 25	13.3
Oct 25	13.06
Oct 25	13.84
Sep 25	13.44
Sep 25	13.57
Sep 25	13.5
Sep 25	14.42
Aug 25	14.55
Aug 25	14.63
Aug 25	14.37
Aug 25	14.31
Aug 25	15.86
Jul 25	16.09
Jul 25	15.62
Jul 25	15.84
Jul 25	15.68
Jun 25	15.05
Jun 25	15
Jun 25	15.33
Jun 25	15.45
May 25	15.84
May 25	15.69
May 25	16.16
May 25	16.05
May 25	16.92
Apr 25	21.07
Apr 25	19.7
Apr 25	18.91
Apr 25	20.06
Mar 25	23.78
Mar 25	23.71
Mar 25	23.12
Mar 25	24.04
Feb 25	23.69
Feb 25	31.34
Feb 25	29.78
Feb 25	29.36
Jan 25	29.09
Jan 25	28.35
Jan 25	28.25
Jan 25	30.94
Jan 25	30.69
Dec 24	30.72
Dec 24	30.15
Dec 24	30.31
Dec 24	30.65
Nov 24	30.32
Nov 24	29.51
Nov 24	29.12
Nov 24	30.8
Nov 24	30.58
Oct 24	40.31
Oct 24	40.53

Price to Book

BMRN Price to Book by year
Period	Price to Book
Sep 26	2
Sep 26	2.03
Aug 26	1.97
Aug 26	2.04
Aug 26	2.06
Aug 26	1.95
Jul 26	1.86
Jul 26	1.84
Jul 26	1.85
Jul 26	1.83
Jul 26	1.83
Jun 26	1.83
Jun 26	1.69
Jun 26	1.73
Jun 26	1.76
May 26	1.78
May 26	1.68
May 26	1.61
May 26	1.68
May 26	1.7
Apr 26	1.68
Apr 26	1.72
Apr 26	1.72
Apr 26	1.75
Mar 26	1.71
Mar 26	1.71
Mar 26	1.84
Mar 26	1.93
Feb 26	1.94
Feb 26	2.03
Feb 26	1.9
Feb 26	1.84
Jan 26	1.79
Jan 26	1.78
Jan 26	1.73
Jan 26	1.87
Jan 26	1.88
Dec 25	1.9
Dec 25	1.94
Dec 25	1.69
Dec 25	1.69
Nov 25	1.77
Nov 25	1.73
Nov 25	1.74
Nov 25	1.63
Oct 25	1.7
Oct 25	1.73
Oct 25	1.69
Oct 25	1.66
Oct 25	1.76
Sep 25	1.71
Sep 25	1.73
Sep 25	1.72
Sep 25	1.83
Aug 25	1.85
Aug 25	1.86
Aug 25	1.83
Aug 25	1.82
Aug 25	1.92
Jul 25	1.95
Jul 25	1.89
Jul 25	1.92
Jul 25	1.9
Jun 25	1.82
Jun 25	1.81
Jun 25	1.85
Jun 25	1.87
May 25	1.91
May 25	1.9
May 25	1.95
May 25	1.94
May 25	2.04
Apr 25	2.13
Apr 25	1.99
Apr 25	1.91
Apr 25	2.03
Mar 25	2.41
Mar 25	2.4
Mar 25	2.34
Mar 25	2.43
Feb 25	2.4
Feb 25	2.4
Feb 25	2.28
Feb 25	2.25
Jan 25	2.23
Jan 25	2.17
Jan 25	2.16
Jan 25	2.37
Jan 25	2.35
Dec 24	2.35
Dec 24	2.31
Dec 24	2.32
Dec 24	2.35
Nov 24	2.32
Nov 24	2.26
Nov 24	2.23
Nov 24	2.36
Nov 24	2.34
Oct 24	2.51
Oct 24	2.52

No video analysis for this stock yet. Request one from our team.

News: BMRN

defenseworld.net · 12 Sep 2026

BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Amundi

Amundi lifted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 37.8% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 259,782 shares of the biotechnology company's stock after acquiring an additional 71,246 shares during the period. Amundi

seekingalpha.com · 10 Sep 2026

BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

seekingalpha.com · 10 Sep 2026

BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

seekingalpha.com · 9 Sep 2026

BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

prnewswire.com · 9 Sep 2026

BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence

Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting VOXZOGO demonstrated statistically significant improvements across multiple measures of growth, including annualized growth velocity, standing height, height Z-score and arm span BioMarin recently submitted a supplemental New Drug Application (sNDA) to the FDA to support expanding treatment with VOXZOGO to include children with hypochondroplasia SAN RAFAEL, Calif., Sept. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO® (vosoritide) in children with hypochondroplasia were published in New England Journal of Medicine (NEJM) Evidence and presented at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting.

zacks.com · 3 Sep 2026

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

prnewswire.com · 2 Sep 2026

BioMarin to Participate in Upcoming Investor Conferences

Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST Cantor Global Healthcare Conference 2026, September 10 at 10:20 am EST Citi's 2026 Biopharma Back to School Conference, September 10 at 1:00 pm EST Morgan Stanley 24th Annual Global Healthcare Conference, September 14 at 10:00 am EST SAN RAFAEL, Calif., Sept. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in September.

zacks.com · 1 Sep 2026

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.